Pay in 4 interest-free payments of $5.47 Learn more
Ships within 48 hours · Estimated delivery Oct 10 - Oct 15
Our analysis found that patients taking tirzepatide were significantly more likely to achieve weight loss: Those taking tirzepatide were 1.8 times more likely than those taking semaglutide to achieve 5% weight loss, 2.5 times more likely than those taking semaglutide to achieve 10% weight loss, And 3.2 times more likely than those taking semaglutide to achieve 15% weight loss
These real-world outcomes help set realistic expectations and identify common challenges you may encounter
This explains the synergy seen with semaglutide combination and positions cagrilintide as a cornerstone of next-generation medical weight loss
Their products are durable, efficient, and built to perfection
Wegovy is approved by the US Food and Drug Administration (FDA) for chronic weight management in adults with a body mass index (BMI) of 30 or higher (classified as obese) or a BMI of 27 or higher (classified as overweight) with at least one weight-related comorbid condition, such as hypertension or type 2 diabetes[1]
